

<b>DMARD</b>	<b>Study</b>	<b>Study design</b>	<b>Total N</b>	<b>Intervention</b>	<b>Intervention sample size</b>	<b>Infection</b>	<b>Psychological condition</b>	<b>Hypertension</b>	<b>Anemia</b>	<b>Lupus or lupus-like syndrome</b>	<b>Stevens-Johnson syndrome</b>
<b>BIOLOGIC AGENTS</b>											
<b>Abatacept</b>	Golmia et al., 2008 <sup>1</sup>	Case report	1	Abatacept	1	-	-	-	-	-	-
	Ruperto et al., 2008 <sup>2</sup>	RCT	190	Abatacept	190	79	-	-	-	-	-
				<b>Total</b>	<b>191</b>	<b>79</b>	-	-	-	-	-
<b>Adalimumab</b>	Burmester et al., 2009 <sup>3</sup>	Series	171	Adalimumab	171	5	-	-	-	-	-
	Cimaz et al., 2010 <sup>4</sup>	Case report	1	Adalimumab	1	-	-	-	-	-	-
	Lovell et al., 2008 <sup>5</sup>	RCT	171	Adalimumab	85	11	-	-	-	-	-
	Lovell et al., 2008 <sup>5</sup>	RCT	171	Adalimumab + MTX	86	18	-	-	-	-	-
				<b>Total</b>	<b>343</b>	<b>34</b>	-	-	-	-	-
<b>Anakinra</b>	Canna et al., 2009 <sup>6</sup>	Case reports	3	Anakinra	3	-	-	-	-	-	-
	Ilowite et al., 2009 <sup>7</sup>	RCT	86	Anakinra	86	25	-	-	-	-	-
	Kone-Paut et al., 2007 <sup>8</sup>	Case report	1	Anakinra	1	1	-	-	-	-	-
	Lequerre et al., 2008 <sup>9</sup>	Series	20	Anakinra	20	5	-	-	-	-	-
	Ohlsson et al., 2008 <sup>10</sup>	Series	7	Anakinra	7	1	-	-	-	-	-
	Zeft et al., 2009 <sup>11</sup>	Series	32	Anakinra	32	1	-	-	-	-	-
				<b>Total</b>	<b>149</b>	<b>33</b>	-	-	-	-	-

<b>DMARD</b>	<b>Study</b>	<b>Study design</b>	<b>Total N</b>	<b>Intervention</b>	<b>Intervention sample size</b>	<b>Infection</b>	<b>Psychological condition</b>	<b>Hypertension</b>	<b>Anemia</b>	<b>Lupus or lupus-like syndrome</b>	<b>Stevens-Johnson syndrome</b>
<b>Etanercept</b>	Bloom, 2000 <sup>12</sup>	Case report	1	Etanercept	1	-	-	-	-	-	-
	Bout-Tabaku et al., 2007 <sup>13</sup>	Case report	1	Etanercept	1	-	-	-	-	1	-
	Dallocchio et al., 2010 <sup>14</sup>	Case reports	8	Etanercept	8	-	-	-	-	-	-
	Elwood et al., 2003 <sup>15</sup>	Case report	1	Etanercept	1	1	-	-	-	-	-
	Fathalla et al., 2008 <sup>16</sup>	Case report	1	Etanercept	1	-	-	-	-	-	-
	Giannini et al., 2009 <sup>17</sup>	Series	103	Etanercept	103	2	13	-	2	-	-
	Horneff et al., 2009 <sup>18</sup>	Series	20	Etanercept	20	11	-	-	-	-	-
	Horneff et al., 2009 <sup>19</sup>	Series	604	Etanercept	100	10	-	-	-	-	-
	Hung et al., 2005 <sup>20</sup>	Case reports	3	Etanercept	3	-	-	-	-	-	-
	Kimura et al., 2005 <sup>21</sup>	Series	82	Etanercept	82	9	-	-	-	-	-
	Kunzmann et al., 2005 <sup>22</sup>	Case report	1	Etanercept	1	-	-	-	-	-	-
	Lepore et al., 2003 <sup>23</sup>	Case report	1	Etanercept	1	-	-	-	-	1	-
	Livermore et al., 2002 <sup>24</sup>	Case report	1	Etanercept	1	-	-	-	-	-	-
	Lovell et al., 2000 <sup>25</sup>	Series	69	Etanercept	69		1	-	-	-	-

<b>DMARD</b>	<b>Study</b>	<b>Study design</b>	<b>Total N</b>	<b>Intervention</b>	<b>Intervention sample size</b>	<b>Infection</b>	<b>Psychological condition</b>	<b>Hypertension</b>	<b>Anemia</b>	<b>Lupus or lupus-like syndrome</b>	<b>Stevens-Johnson syndrome</b>
	Lovell et al., 2003 <sup>26</sup>	Series	58	Etanercept	58	9	-	-	-	-	-
	Mangge et al., 2003 <sup>27</sup>	Case report	1	Etanercept	1	-	-	-	-	-	-
	Mene et al., 2010 <sup>28</sup>	Case report	1	Etanercept	1	-	-	-	-	-	-
	Mori et al., 2005 <sup>29</sup>	Series	22	Etanercept	22	16	-	-	-	-	-
	Morishita et al., 2010 <sup>30</sup>	Case reports	2	Etanercept	2	2	-	-	-	-	-
	Peek et al., 2006 <sup>31</sup>	Case report	1	Etanercept	1	-	-	-	-	-	-
	Prince et al., 2009 <sup>32</sup>	Series	146	Etanercept	146	8	3	-	-	-	-
	Quartier et al., 2003 <sup>33</sup>	Series	61	Etanercept	61	-	8	-	-	-	-
	Ramanan et al., 2003 <sup>34</sup>	Case report	1	Etanercept	1	-	-	-	-	-	-
	Robinson et al., 2003 <sup>35</sup>	Series	21	Etanercept	21	1	-	-	-	-	-
	Skytta et al., 2000 <sup>36</sup>	Case reports	2	Etanercept	2	-	-	-	-	-	-
	Smith et al., 2005 <sup>37</sup>	RCT	12	Etanercept	7	21	-	-	-	-	-
	Takei et al., 2001 <sup>38</sup>	Series	8	Etanercept	8	-	-	-	-	-	-
	Tauber et al., 2005 <sup>39</sup>	Case reports	2	Etanercept	2	-	-	-	-	-	-
	Tauber et al., 2006 <sup>40</sup>	Case reports	2	Etanercept	2	-	-	-	-	-	-

<b>DMARD</b>	<b>Study</b>	<b>Study design</b>	<b>Total N</b>	<b>Intervention</b>	<b>Intervention sample size</b>	<b>Infection</b>	<b>Psychological condition</b>	<b>Hypertension</b>	<b>Anemia</b>	<b>Lupus or lupus-like syndrome</b>	<b>Stevens-Johnson syndrome</b>
	Tynjala et al., 2007 <sup>41</sup>	Series	45	Etanercept	24	2	-	-	-	-	-
	Tzaribachev et al., 2008 <sup>42</sup>	Series	25	Etanercept	25	1	-	-	-	-	-
	Wiegering et al., 2010 <sup>43</sup>	Case report	1	Etanercept	1	-	-	-	-	-	-
	Aikawa et al., 2009 <sup>44</sup>	Case report	1	Etanercept + MTX	1	-	-	-	-	-	-
	Billiau et al., 2010 <sup>45</sup>	Series	16	Etanercept + MTX	16	2	-	-	-	-	-
	Fitch et al., 2006 <sup>46</sup>	Case report	1	Etanercept + MTX	1	1	-	-	-	-	-
	Giannini et al., 2009 <sup>17</sup>	Series	294	Etanercept + MTX	294	-	33	-	1	-	-
	Holl-Wieden et al., 2008 <sup>47</sup>	Case report	1	Etanercept + MTX	1	1	-	-	-	-	-
	Horneff et al., 2004 <sup>48</sup>	Series	322	Etanercept + MTX	322	10	-	-	-	-	-
	Horneff et al., 2009 <sup>19</sup>	Series	604	Etanercept + MTX	504	63	-	-	-	-	1
	Kuemmerle-Deschner et al., 2007 <sup>49</sup>	Series	12	Etanercept + MTX	12	1	-	-	-	-	-
	Yildirim-Toruner et al., 2008 <sup>50</sup>	Correspondence	1	Etanercept + MTX	1	-	-	-	-	-	-
				<b>Total</b>	<b>1929</b>	<b>171</b>	<b>58</b>	-	<b>3</b>	<b>2</b>	<b>1</b>
				<b>Incidence – Etanercept</b>		<b>9%</b>	<b>3%</b>	-	<b>0%</b>	<b>0%</b>	<b>0%</b>

<b>DMARD</b>	<b>Study</b>	<b>Study design</b>	<b>Total N</b>	<b>Intervention</b>	<b>Intervention sample size</b>	<b>Infection</b>	<b>Psychological condition</b>	<b>Hypertension</b>	<b>Anemia</b>	<b>Lupus or lupus-like syndrome</b>	<b>Stevens-Johnson syndrome</b>
<b>IVIG</b>	Aggarwal et al., 2004 <sup>51</sup>	Series	214	IVIG	1	-	-	-	-	-	-
	de Castro et al., 2003 <sup>52</sup>	Case reports	5	IVIG	1	-	-	-	-	-	-
	Prieur et al., 1990 <sup>53</sup>	Series	16	IVIG	16	-	-	-	-	-	-
	Silverman et al., 1994 <sup>54</sup>	RCT	31	IVIG	14	-	-	-	-	-	-
	Uziel et al., 1996 <sup>55</sup>	Series	27	IVIG	27	-	-	-	-	1	-
				<b>Total</b>	<b>60</b>	-	-	-	-	<b>1</b>	-
<b>Infliximab</b>	Armbrust et al., 2004 <sup>56</sup>	Case report	1	Infliximab	1	1	-	-	-	-	-
	Becker et al., 2004 <sup>57</sup>	Case reports	3	Infliximab	3	-	-	-	-	-	-
	Billiau et al., 2002 <sup>59</sup>	Case reports	3	Infliximab	3	2	-	-	-	-	-
	Corona et al., 2004 <sup>58</sup>	Series	9	Infliximab	9	-	-	-	-	-	-
	Katsicas et al., 2005 <sup>60</sup>	Series	6	Infliximab	6	-	-	-	-	-	-
	Lahdenne et al., 2003 <sup>61</sup>	Series	24	Infliximab	14	-	-	-	-	-	-
	Mangge et al., 2003 <sup>62</sup>	Case report	1	Infliximab	1	-	-	-	-	-	-
	Morishita et al., 2010 <sup>30</sup>	Case reports	2	Infliximab	2	2	-	-	-	-	-

<b>DMARD</b>	<b>Study</b>	<b>Study design</b>	<b>Total N</b>	<b>Intervention</b>	<b>Intervention sample size</b>	<b>Infection</b>	<b>Psychological condition</b>	<b>Hypertension</b>	<b>Anemia</b>	<b>Lupus or lupus-like syndrome</b>	<b>Stevens-Johnson syndrome</b>
	Pipitone et al., 2005 <sup>63</sup>	Case report	1	Infliximab	1	-	-	-	-	-	-
	Simonini et al., 2008 <sup>64</sup>	Series	15	Infliximab	15	-	-	-	-	-	-
	Tutar et al., 2004 <sup>65</sup>	Case reports	2	Infliximab	2	1	-	-	-	-	-
	Tyler et al., 2007 <sup>66</sup>	Case report	1	Infliximab	1	-	-	-	1	-	-
	Tynjala et al., 2007 <sup>41</sup>	Series	45	Infliximab	21	-	-	-	-	-	-
	Ruperto et al., 2007 <sup>67</sup>	RCT	122	Infliximab + MTX	60	46	-	-		-	-
	Ruperto et al., 2010 <sup>68</sup>	Post-RCT open-label trial	78	Infliximab + MTX	78	57	-	-	-	-	-
	Yildirim-Toruner et al., 2008 <sup>50</sup>	Case reports	2	Infliximab	2	-	-	-	-	-	-
				<b>Total</b>	<b>219</b>	<b>109</b>	-	-	1	-	-
<b>Leflunomide</b>	Foeldvari and Wierk, 2010 <sup>69</sup>	Series	58	Leflunomide	58	-	-	1	-	-	-
	Silverman et al., 2005 <sup>70</sup>	RCT	94	Leflunomide	47	6	-	-		-	-
	Silverman et al., 2005 <sup>71</sup>	Series	27	Leflunomide	27	12	-	-	4	-	-
				<b>Total</b>	<b>74132</b>	<b>18</b>	-	1	4	-	-

<b>DMARD</b>	<b>Study</b>	<b>Study design</b>	<b>Total N</b>	<b>Intervention</b>	<b>Intervention sample size</b>	<b>Infection</b>	<b>Psychological condition</b>	<b>Hypertension</b>	<b>Anemia</b>	<b>Lupus or lupus-like syndrome</b>	<b>Stevens-Johnson syndrome</b>
<b>Tocilizumab</b>	Woo et al., 2005 <sup>72</sup>	RCT	18	Tocilizumab	18	2	-	-	-	-	-
	Yokota et al., 2008 <sup>73</sup>	RCT	56	Tocilizumab	56	1	-	-	-	-	-
				<b>Total</b>	<b>74</b>	<b>3</b>	-	-	-	-	-
				<b>Total – Biologics</b>	<b>3097</b>	<b>447</b>	<b>58</b>	<b>1</b>	<b>8</b>	<b>3</b>	<b>1</b>
				<b>Incidence – Biologics</b>			<b>14%</b>	<b>2%</b>	<b>0%</b>	<b>0%</b>	<b>0%</b>
<b>NON-BIOLOGIC AGENTS</b>											
<b>Azathioprine</b>	Aggarwal et al., 2004 <sup>51</sup>	Series	214	Azathioprine	5	-	-	-	-	-	-
	de Castro et al., 2003 <sup>52</sup>	Case reports	5	Azathioprine	2	-	-	-	-	-	-
	Kvien et al., 1986 <sup>74</sup>	RCT	32	Azathioprine	17	3	-	-	-	-	-
	Lin et al., 2000 <sup>75</sup>	Series	24	Azathioprine	24	-	-	-	-	-	-
	Savolainen et al., 1997 <sup>76</sup>	Series	129	Azathioprine	129	-	-	-	-	-	-
	de Castro et al., 2003 <sup>52</sup>	Case reports	5	Azathioprine + MTX	5	-	-	-	-	-	-
				<b>Total</b>	<b>182</b>	<b>3</b>	-	-	-	-	-
<b>Cyclosporine A</b>	de Castro et al., 2003 <sup>52</sup>	Case reports	5	Cyclosporine A	2	-	-	-	-	-	-
	Gattinara et al., 1994 <sup>77</sup>	Case reports	50 35 w/ JRA	Cyclosporine A	50	8	-	-	-	-	-

<b>DMARD</b>	<b>Study</b>	<b>Study design</b>	<b>Total N</b>	<b>Intervention</b>	<b>Intervention sample size</b>	<b>Infection</b>	<b>Psychological condition</b>	<b>Hypertension</b>	<b>Anemia</b>	<b>Lupus or lupus-like syndrome</b>	<b>Stevens-Johnson syndrome</b>
	Gerloni et al., 2001 <sup>78</sup>	Series	41	Cyclosporine A	41	3	-	6	-	-	-
	de Castro et al., 2003 <sup>52</sup>	Case reports	5	Cyclosporine A + MTX	1	-	-	1	-	-	-
	Krugmann et al., 2000 <sup>79</sup>	Case report	1	Cyclosporine A + MTX	1	-	-	-	-	-	-
	Mateicka et al., 1994 <sup>80</sup>	Series	3	Cyclosporine A	3	-	-	1	-	-	-
	Murphy et al., 1993 <sup>81</sup>	Case report	1	Cyclosporine A	1	-	-	-	-	-	-
	Ostensen et al., 1988 <sup>82</sup>	Series	14	Cyclosporine A	14	-	-	1	-	-	-
	Pistoia et al., 1993 <sup>83</sup>	Series	9	Cyclosporine A	9	-	-	2	-	-	-
	Ruperto et al., 2006 <sup>84</sup>	Series	329	Cyclosporine A	329	-	-	6	-	-	-
	Ravelli et al., 2002 <sup>85</sup>	Series	17	Cyclosporine A + MTX	17	-	-	-	-	-	-
				<b>Total</b>	<b>468</b>	<b>11</b>	<b>-</b>	<b>17</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>Penicillamine</b>	Aggarwal et al., 2004 <sup>51</sup>	Series	214	Penicillamine	23	-	-	-	-	-	-
	Kvien et al., 1985 <sup>86</sup>	RCT	77	Penicillamine	38	-	-	-	-	-	-
	Prieur et al., 1985 <sup>87</sup>	RCT	74	Penicillamine	74	2	-	-	-	-	-
	Sahn et al., 1989 <sup>88</sup>	Case report	1	Penicillamine	1	-	-	-	-	-	-

<b>DMARD</b>	<b>Study</b>	<b>Study design</b>	<b>Total N</b>	<b>Intervention</b>	<b>Intervention sample size</b>	<b>Infection</b>	<b>Psychological condition</b>	<b>Hypertension</b>	<b>Anemia</b>	<b>Lupus or lupus-like syndrome</b>	<b>Stevens-Johnson syndrome</b>
	Brewer et al., 1986 <sup>89</sup>	RCT	162	Penicillamine	54	-	-	-	-	-	-
	Kvien et al., 1985 <sup>90</sup>	RCT	72	Penicillamine	24	-	-	-	-	-	-
	Swartz et al., 1984 <sup>91</sup>	Case report	1	Penicillamine	1	-	-	-	-	-	-
				<b>Total</b>	<b>215</b>	<b>2</b>	-	-	-	-	-
<b>Methotrexate</b>	Aggarwal et al., 2004 <sup>51</sup>	Series	214	Methotrexate	118	2	-	-	4	-	-
	Arakawa et al., 2003 <sup>92</sup>	Case report	1	Methotrexate	1	-	-	-	-	-	-
	Becker et al., 2010 <sup>93</sup>	Series	220	Methotrexate	220	-	-	-	-	-	-
	Chedeville et al., 2005 <sup>94</sup>	Series	27	Methotrexate	27	-	-	-	-	-	-
	Cleary et al., 2002 <sup>95</sup>	Case report	1	Methotrexate	1	-	-	-	-	-	-
	Corona et al., 1993 <sup>96</sup>	Series	34	Methotrexate	34	-	-	-	-	-	-
	Cron et al., 1998 <sup>97</sup>	Case report	1	Methotrexate	1	-	-	-	-	-	-
	de Castro et al., 2003 <sup>52</sup>	Case reports	5	Methotrexate	4	-	-	-	-	-	-
	Douglas Graham et al., 1992 <sup>98</sup>	Series	62	Methotrexate	62	12	-	-	1	-	-
	Falcini et al., 1997 <sup>99</sup>	Case report	1	Methotrexate	1	-	-	-	-	-	-

<b>DMARD</b>	<b>Study</b>	<b>Study design</b>	<b>Total N</b>	<b>Intervention</b>	<b>Intervention sample size</b>	<b>Infection</b>	<b>Psychological condition</b>	<b>Hypertension</b>	<b>Anemia</b>	<b>Lupus or lupus-like syndrome</b>	<b>Stevens-Johnson syndrome</b>
	Giannini et al., 1992 <sup>100</sup>	RCT	127	Methotrexate	86	-	-	-	-	-	-
	Giannini et al., 2009 <sup>17</sup>	Series	197	Methotrexate	197	-	15	-	1	-	-
	Gottlieb et al., 1997 <sup>101</sup>	Series	25	Methotrexate	25	1	-	-	-	-	-
	Graham et al., 1992 <sup>102</sup>	Series	62	Methotrexate	62	12	-	-	1	-	-
	Halle et al., 1991 <sup>103</sup>	Series	30	Methotrexate	30	1	-	-	-	-	-
	Huang et al., 1996 <sup>104</sup>	Series	26	Methotrexate	26	-	-	-	-	-	-
	Hunstad et al., 2007 <sup>105</sup>	Case report	1	Methotrexate	1	1	-	-	-	-	-
	Keim et al., 1990 <sup>106</sup>	Case report	1	Methotrexate	1	-	-	-	-	-	-
	Lee et al., 2006 <sup>107</sup>	Series	84	Methotrexate	46	-	-	-	-	-	-
	Lee et al., 2009 <sup>108</sup>	Case report	1	Methotrexate	1	-	-	-	-	-	-
	Lin et al., 2000 <sup>109</sup>	Series	52	Methotrexate	52	1	-	-	-	-	-
	Londino et al., 1998 <sup>110</sup>	Case report	1	Methotrexate	1	-	-	-	-	-	-
	Martini et al., 1991 <sup>111</sup>	Series	27	Methotrexate	27	-	-	-	-	-	-
	Muzaffer et al., 1996 <sup>112</sup>	Case reports	2	Methotrexate	2	-	-	-	-	-	-
	Ortiz-Alvarez et al., 2004 <sup>113</sup>	Series	89	Methotrexate	89	-	-	-	-	-	-

<b>DMARD</b>	<b>Study</b>	<b>Study design</b>	<b>Total N</b>	<b>Intervention</b>	<b>Intervention sample size</b>	<b>Infection</b>	<b>Psychological condition</b>	<b>Hypertension</b>	<b>Anemia</b>	<b>Lupus or lupus-like syndrome</b>	<b>Stevens-Johnson syndrome</b>
	Padeh et al., 1997 <sup>114</sup>	Case report	1	Methotrexate	1	-	-	-	-	-	-
	Ravelli et al., 1996 <sup>115</sup>	Case report	1	Methotrexate	1	-	-	-	-	-	-
	Ravelli et al., 1998 <sup>116</sup>	Series	256	Methotrexate	256	-	-	-	-	-	-
	Ravelli et al., 2001 <sup>117</sup>	Case report	1	Methotrexate	1	-	-	-	-	-	-
	Riddle et al., 2006 <sup>118</sup>	Series	57	Methotrexate	20	-	-	-	-	-	-
	Rose et al., 1990 <sup>119</sup>	Series	29	Methotrexate	29	-	-	-	-	-	-
	Ruperto et al., 2004 <sup>120</sup>	RCT	595	Methotrexate	595	-	-	-	-	-	-
	Russo et al., 2000 <sup>121</sup>	Series	20	Methotrexate	20	-	-	-	-	-	-
	Savolainen et al., 2001 <sup>122</sup>	Case reports	2	Methotrexate	2	-	-	-	-	-	-
	Schmeling et al., 2005 <sup>123</sup>	Series	58	Methotrexate	58	-	-	-	-	-	-
	Silverman et al., 2005 <sup>70</sup>	RCT	94	Methotrexate	47	2	-	-	-	-	-
	Speckmaier et al., 1989 <sup>124</sup>	Series	12	Methotrexate	12	-	1	-	-	-	-
	Takeyama et al., 2006 <sup>125</sup>	Case report	1	Methotrexate	1	1	-	-	-	-	-

<b>DMARD</b>	<b>Study</b>	<b>Study design</b>	<b>Total N</b>	<b>Intervention</b>	<b>Intervention sample size</b>	<b>Infection</b>	<b>Psychological condition</b>	<b>Hypertension</b>	<b>Anemia</b>	<b>Lupus or lupus-like syndrome</b>	<b>Stevens-Johnson syndrome</b>
	Truckenbrodt et al., 1986 <sup>126</sup>	Series	19	Methotrexate	12	1	-	-	-	-	-
	van der Meer et al., 2007 <sup>127</sup>	Series	29	Methotrexate	29	-	17	-	-	-	-
	Wallace et al., 1992 <sup>128</sup>	Series	13	Methotrexate	13	-	-	-	-	-	-
	Yildirim et al., 2000 <sup>129</sup>	Case report	1	Methotrexate	1	-	-	-	-	-	-
	Kocharla et al., 2009 <sup>130</sup>	Series	588	Methotrexate + folic acid	198	-	-	-	-	-	-
				<b>Total</b>	<b>2411</b>	<b>34</b>	<b>33</b>	-	<b>1</b>	-	-
				<b>Incidence – Methotrexate</b>		<b>1%</b>	<b>1%</b>	-	<b>0%</b>	-	-
<b>Sulfasalazine</b>	Balci et al., 2009 <sup>131</sup>	Case report	1	Sulfasalazine	1	-	-	-	-	-	-
	Burgos-Vargas et al., 2002 <sup>132</sup>	RCT	33	Sulfasalazine	17	-	-	-	-	-	-
	Chen et al., 2002 <sup>133</sup>	Series	24	Sulfasalazine	24	-	-	-	-	-	-
	de Castro et al., 2003 <sup>52</sup>	Case reports	5	Sulfasalazine	1	-	-	-	-	-	-
	Hertzbergerten Cate et al., 1991 <sup>134</sup>	Series	3	Sulfasalazine	3	-	-	-	-	-	-
	Imundo et al., 1996 <sup>135</sup>	Series	139	Sulfasalazine	139	-	-	-	-	-	-
	Joos et al., 1991 <sup>136</sup>	Series	41	Sulfasalazine	41	-	1	-	-	-	-

<b>DMARD</b>	<b>Study</b>	<b>Study design</b>	<b>Total N</b>	<b>Intervention</b>	<b>Intervention sample size</b>	<b>Infection</b>	<b>Psychological condition</b>	<b>Hypertension</b>	<b>Anemia</b>	<b>Lupus or lupus-like syndrome</b>	<b>Stevens-Johnson syndrome</b>
	van Rossum et al., 1998 <sup>137</sup>	RCT	69	Sulfasalazine	35	-	-	-	-	-	-
	van Rossum et al., 2007 <sup>138</sup>	Series	61	Sulfasalazine	32	-	-	-	-	-	-
	Aggarwal et al., 2004 <sup>51</sup>	Series	214	Sulfasalazine	28	-	-	-	-	-	-
	Ansell et al., 1991 <sup>139</sup>	Series	51	Sulfasalazine	51	-	-	-	-	-	-
	Gedalia et al., 1993 <sup>140</sup>	Series	10	Sulfasalazine	10	-	-	-	-	-	-
	Gunnarson et al., 1997 <sup>141</sup>	Series	8	Sulfasalazine	8	-	-	-	-	8	-
	Huang et al., 1998 <sup>142</sup>	Series	15	Sulfasalazine	15	-	-	-	-	-	-
	Huang et al., 1998 <sup>143</sup>	Case report	1	Sulfasalazine	1	-	-	-	-	-	-
	Kummerle-Deschner et al., 1995 <sup>144</sup>	Case report	1	Sulfasalazine	1	-	-	-	-	-	-
	Ozdogan et al., 1986 <sup>145</sup>	Series	18	Sulfasalazine	18	-	-	-	-	-	-
	Pinana et al., 2010 <sup>146</sup>	Case report	1	Sulfasalazine	1	1	-	-	-	-	-
	Settas et al., 1991 <sup>147</sup>	Series	18	Sulfasalazine	18	-	-	-	-	-	-

<b>DMARD</b>	<b>Study</b>	<b>Study design</b>	<b>Total N</b>	<b>Intervention</b>	<b>Intervention sample size</b>	<b>Infection</b>	<b>Psychological condition</b>	<b>Hypertension</b>	<b>Anemia</b>	<b>Lupus or lupus-like syndrome</b>	<b>Stevens-Johnson syndrome</b>
	Varbanova et al., 1999 <sup>148</sup>	Series	32	Sulfasalazine	32	-	-	-	-	-	-
				<b>Total</b>	<b>476</b>	<b>1</b>	<b>1</b>	-	-	-	<b>0</b>
				<b>Incidence – Sulfasalazine</b>		<b>0%</b>	<b>0%</b>	-	-	-	<b>0%</b>
<b>OTHER</b>											
	Flato et al., 1998 <sup>149</sup>	Series	117	DMARDs	28	-	-	-	-	-	-
	Lomater et al., 1994 <sup>150</sup>	Series	7	Plaquenil + MTX + gold salts	7	-	-	-	-	-	-
	Barash et al., 199 <sup>151</sup>	Case reports	2	Penicillamine + gold	2	-	-	-	-	-	-